CCR5 antagonists useful for treating aids

US6720325B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventor

• Michael Miller · Scotch Plains, US

Key dates

• Filing date: Mar 27, 2002
• Grant date: Apr 13, 2004
• Expiry date: Mar 27, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formula or a pharmaceutically acceptable salt or isomer thereof, wherein:Q, X and Z are CH or N;R, R4—R7 and R13 are H or alkyl;R1 is H, alkyl, fluoroalkyl, R9-arylalkyl, R9-heteroarylalkyl, alkyl-SO2—, cycloalkyl-SO2—, fluoroalkyl-SO2—, R9-aryl-SO2—, R9-heteroaryl-SO2—, N(R22)(R23)—SO2—, alkyl-C(O)—, cycloalkyl-C(O)—, fluoroalkyl-C(O)—, R9-aryl-C(O)—, NH-alkyl-C(O)— or R9-aryl-NH—C(O)—;R2 is H and R3 is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R9-aryl, R9-arylalkyl, R9-heteroaryl, or R9-heteroarylalkyl, and when X and Z are each CH, R3 is alkoxy, R9-aryloxy, R9-heteroaryloxy, alkylC(O)O—, alkylaminoC(O)O—, alkylC(O)NR13—, alkylOC(O)NR13— or alkylaminoC(O)NR13—;or R2 and R3 together are ═O, ═NOR10, ═N—NR11R12 or ═CH-alkyl;R8 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenymethyl, alpha-substituted benzyl or alpha-substituted heteroarylmethyl;R9—R12 are as defined;are disclosed for the treatment of HIV, solid organ transplant rejection, graft v. host disease, inflammatory disease…